Notícias e Atividades da Crinetics Pharmaceuticals

Crinetics Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Crinetics Pharmaceuticals é uma empresa listada sob o símbolo CRNX (US).

Veja o organograma con seus 24 executivos principais

Biografias mais buscadas da Crinetics Pharmaceuticals

• Scott Struthers, Chief Executive Officer and Director
• Camille Bedrosian, Director
• Wendell Wierenga, Chairman of the Board

Recentes movimentos de executivos em Crinetics Pharmaceuticals

• Marc Wilson, Chief Financial Officer, deixará a Companhia em 28 de fev. de 2025  (Notícia publicada em 24 de fevereiro de 2025).
• Tobin Schilke ingressará na Companhia como Chief Financial Officer em 28 de fev. de 2025  (Notícia publicada em 24 de fevereiro de 2025).
• Isabel Kalofonos, ingressou na Companhia como Chief Commercial Officer  (Notícia publicada em 16 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Crinetics Pharmaceuticals

• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals to Participate in September Investor Conferences - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly - Crinetics Pharmaceuticals
• Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine - Crinetics Pharmaceuticals
• View more press releases Close

Redes sociais sobre Crinetics Pharmaceuticals

• Crinetics Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Crinetics Pharmaceuticals na LinkedIn, Twitter e YouTube